Shaping Medicine’s Landscape: Engineered Cell Therapy Market’s Influence

New Delhi: The global engineered cell therapy market was anticipated to reach a valuation of US$ 4.2 Billion in the year 2022. With a robust CAGR of 14.7% from 2023 to 2033, this market is expected to reach US$ 4.82 Billion by 2023 and US$ 18.99 Billion by 2033.

New cell types are continuously entering the engineered cell therapy industry, providing tremendous opportunities for businesses to improve their market positions. As a result, the number of businesses working on the development of cell treatments has dramatically increased during the past several years. Other key reasons impacting the expansion in the number of firms in the market are the rise in financing for cell therapy biomedical studies, the adoption of practical standards for cell therapy production, and the success of innovative products.

A decrease in the price of engineered cell treatments has also increased consumer interest.

The creation of cell banking facilities and the subsequent expansion of cell production, storage, and characterization have improved the market’s capacity to deal with significant volumes on a worldwide basis. The market’s improved income creation over the preceding several years has been directly attributed to this.

Some of the significant factors that are responsible for propelling the global engineered cell therapy market are:

·         Rising investments in various cell-based research from different government

·         Increasing incidence of both infectious and chronic diseases

·         Increasing number of clinical trials towards cell therapy related to oncology

·         Rising GMP certification for engineered cell therapy production centers

The existence of both public and commercial financing organizations, which routinely provide approvals to projects to assist throughout all phases of clinical trials, can be linked to a rise in the number of clinical studies. Most late-stage initiatives in Europe receive funding from grants from the EU. For instance, Achilles Therapeutics announced in July 2022 that it had received the “Horizon Europe” grant, worth USD 4.2 million. It is the main financing program for research and innovation in the EU. The production of tailored therapies will advance thanks to this support. Such developments are anticipated to open up new avenues for this market from 2023 to 2033.

In the upcoming years, the market is anticipated to increase significantly in the domain of musculoskeletal problems. Much research is being done to develop technologies that make it easier for injured musculoskeletal tissues to regenerate or be repaired. Diverse research teams examine the therapeutically relevant cell types that are used in treatments for the degeneration of musculoskeletal tissues and use engineered or native skeletal progenitor cells to stimulate tissue repair and revitalize musculoskeletal tissues.

With a 52% market share in 2022, North America had the highest share of the engineered cell therapy market. This is a result of regional pharmaceutical industry titans and academic institutes collaborating on research projects. With several partnerships, there are new developments in the area. For instance, Immatics and Bristol Myers Squibb worked together to create the Gamma Delta Allogeneic Cell Therapy Programme in June 2022. Immatics as well as Bristol Myers will jointly develop two projects that Bristol Myers Squibb will own, and both companies have the potential to develop a total of four more treatments.

By pushing it to physicians for use in transplant surgeries, leading players in the industry are launching a variety of campaigns to grow their client base. Also, to improve their market position, these businesses are launching new products and engaging in partnerships, collaborations, mergers, and acquisitions. For instance, 2seventy Bio and Regeneron signed an extended translational partnership agreement in January 2023 to develop novel cell therapy-based drug combinations for solid malignancies. Also, in September 2021, Adaptimmune Therapeutics plc announced a partnership with Genentech for the creation and promotion of allogeneic treatments that would be used to treat a variety of oncology-related illnesses. These developments are expected to propel the demand in this global market during the forecast period.

Engineered cell therapy Market: Drivers and Restraints

Tissue engineering has helped to overcome the damaged tissues. There are end number of patients globally waiting for the organ transplantation. Meanwhile, Owing to the limited organ donors’ availability, organ transplantation has become too difficult. Engineered cell therapy is managing the gap with this aspect.

Rising research investments for cell therapy and tissue engineering is aiding to fuel the engineered cell therapy market growth. Engineered cell therapy is advantageous and overcoming the varied barriers for providing treatment to the patients. However, the method is very expensive, thus it is posing as the threat to the growth of the engineered cell therapy market.

Engineered cell therapy Market: Overview

The cardiovascular segment is estimated to boosts the market growth due to the increasing cases of cardiovascular diseases worldwide. Additionally, the major players are associated with the development of engineered cell therapies to restore and re-vascularize the deface heart tissues.

Moreover, the biologics, gene therapy, and macromolecules are being observed to incite the restoration of damaged heart cells. Additionally, the diagnostic centers segment held the largest share owing to the rising research and development activities and the utilization of engineered cell therapy in molecular diagnostics. While the biologically derived materials have a major role in the development of cellular engineering therapy that increases the restorative potential to human tissues to restore the normal body function, in the case of damage.

Engineered cell therapy Market: Regional Wise Outlook

Geographically, the engineered cell therapy market is segregated into seven regions viz. Asia Pacific, North America & Latin America, Eastern Europe Western Europe, Japan, & the Middle East and Africa. North America is projected to ascendant the engineered cell therapy market followed by Asia Pacific & Europe. North America has a major market share due to the awareness for engineered cell therapy in the geriatric populace.

---

These insights are based on a report Engineered Cell Therapy Market by Future Market Insights.